CPSF4 and metabolic dysfunction-associated steatotic liver disease: In conclusion, these findings suggest that NP-NAR may be a promising candidate for the treatment of obesity-associated MASLD, offering new insight into the mechanisms underlying NAR’s efficacy against MASLD.